IDEXX Laboratories, Inc. (NASDAQ:IDXX) saw unusually large options trading activity on Thursday. Stock traders purchased 1,558 put options on the stock. This is an increase of Infinity compared to the average daily volume of 0 put options.

IDEXX Laboratories (NASDAQ:IDXX) opened at $155.49 on Friday. The company has a current ratio of 0.95, a quick ratio of 0.75 and a debt-to-equity ratio of -12.48. The company has a market capitalization of $13,561.68, a P/E ratio of 52.35, a PEG ratio of 2.35 and a beta of 0.46. IDEXX Laboratories has a 52-week low of $104.21 and a 52-week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. The firm had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. sell-side analysts predict that IDEXX Laboratories will post 3.24 earnings per share for the current fiscal year.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the transaction, the chairman now directly owns 1,044,034 shares in the company, valued at approximately $157,429,886.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jonathan W. Ayers sold 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $154.54, for a total value of $2,627,180.00. Following the completion of the transaction, the chairman now owns 1,039,034 shares of the company’s stock, valued at $160,572,314.36. The disclosure for this sale can be found here. Insiders sold a total of 151,734 shares of company stock valued at $23,436,626 over the last three months. 2.77% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of IDXX. D.A. Davidson & CO. boosted its position in shares of IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after acquiring an additional 385 shares during the last quarter. Sun Life Financial INC boosted its position in shares of IDEXX Laboratories by 9,085.7% during the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after acquiring an additional 636 shares during the last quarter. BB&T Investment Services Inc. bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $104,000. Capital Advisors Ltd. LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $128,000. Finally, Coastline Trust Co bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $202,000. Hedge funds and other institutional investors own 87.63% of the company’s stock.

Several research analysts have weighed in on IDXX shares. Canaccord Genuity restated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Bank of America Corporation upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research note on Wednesday, August 23rd. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Monday, August 21st. CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Friday, July 28th. Finally, Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price target for the company in a research note on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Hold” and an average target price of $173.67.

WARNING: “IDEXX Laboratories Target of Unusually Large Options Trading (IDXX)” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/05/idexx-laboratories-target-of-unusually-large-options-trading-idxx.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.